Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference

Printer friendly version
Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference
PRINCETON, N.J., April 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ --
Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the
Morgan Stanley Global Healthcare Unplugged Conference at 10:30 a.m. EDT on
Wednesday, April 30, 2008.  The event will be webcast live and will be available in
the Investor Relations section of the Medarex website at www.medarex.com.  An
archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and
potential commercialization of fully human antibody-based therapeutics to treat
life-threatening and debilitating diseases, including cancer, inflammation,
autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R)
technology and product development and clinical manufacturing experience to
generate, support and potentially commercialize a broad range of fully human
antibody product candidates for itself and its partners. More than 40 of these
therapeutic product candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with seven of the most advanced
product candidates currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's unmet
healthcare needs. For more information about Medarex, visit its website at
www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex,
Inc.  All rights are reserved.

SOURCE  Medarex, Inc.

http://www.medarex.com